180 related articles for article (PubMed ID: 36618573)
1. Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study.
Takeuchi M; Nakai S; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Saudi J Ophthalmol; 2022; 36(4):380-386. PubMed ID: 36618573
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study.
Nakai S; Takeuchi M; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Ocul Immunol Inflamm; 2024 May; 32(4):367-375. PubMed ID: 35748779
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
4. Identification of Underlying Inflammation in Vogt-Koyanagi-Harada Disease with Sunset Glow Fundus by Multiple Analyses.
Murata T; Sako N; Takayama K; Harimoto K; Kanda K; Herbort CP; Takeuchi M
J Ophthalmol; 2019; 2019():3853794. PubMed ID: 31687197
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease.
Guo K; Xu X; Yang F; Wang K; Zhang X
Ocul Immunol Inflamm; 2024 May; ():1-11. PubMed ID: 38709230
[TBL] [Abstract][Full Text] [Related]
7. Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs.
Komuku Y; Ishikawa H; Ide A; Matsuoka T; Fukuyama H; Okadome T; Gomi F
Transl Vis Sci Technol; 2020 Oct; 9(11):10. PubMed ID: 33133773
[TBL] [Abstract][Full Text] [Related]
8. Treatment and Prognosis of Vogt-Koyanagi-Harada Disease: Real-Life Experience in Long-Term Follow-Up.
Accorinti M; Saturno MC; Iannetti L; Manni P; Mastromarino D; Pirraglia MP
J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806916
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of pretreatment indocyanine green angiography in the acute uveitic phase of Vogt-Koyanagi-Harada disease.
Tobaigy MF; Abouammoh MA; AlBloushi AF; Saifaldein AA; Gikandi P; Almousa AN; Herbort CP; El-Asrar AA
Acta Ophthalmol; 2023 Dec; ():. PubMed ID: 38131519
[TBL] [Abstract][Full Text] [Related]
10. A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada disease.
Lee EK; Lee SY; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):359-68. PubMed ID: 25017008
[TBL] [Abstract][Full Text] [Related]
11. The effect on choroidal changes of the route of systemic corticosteroids in acute Vogt-Koyanagi-Harada disease.
Park UC; Cho IH; Lee EK; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1203-1211. PubMed ID: 28382438
[TBL] [Abstract][Full Text] [Related]
12. Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation.
Keino H; Goto H; Usui M
Graefes Arch Clin Exp Ophthalmol; 2002 Oct; 240(10):878-82. PubMed ID: 12397437
[TBL] [Abstract][Full Text] [Related]
13. Indocyanine green angiography guided management of vogt-koyanagi-harada disease.
Bouchenaki N; Herbort CP
J Ophthalmic Vis Res; 2011 Oct; 6(4):241-8. PubMed ID: 22454746
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy.
Yang S; Tao T; Huang Z; Liu X; Li H; Xie L; Wen F; Chi W; Su W
Front Med (Lausanne); 2021; 8():799427. PubMed ID: 35096888
[No Abstract] [Full Text] [Related]
15. Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients.
Yang S; Tao T; Li Z; Chen B; Huang Z; Liu X; Li H; Xie L; Feng W; Su W
Ann Transl Med; 2022 Jun; 10(12):699. PubMed ID: 35845536
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
17. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease.
Inomata H; Rao NA
Am J Ophthalmol; 2001 May; 131(5):607-14. PubMed ID: 11336935
[TBL] [Abstract][Full Text] [Related]
18. EFFICACY OF COMBINED SYSTEMIC CORTICOSTEROID AND EARLY IMMUNOMODULATORY THERAPY WITHIN THREE MONTHS OF ONSET IN VOGT-KOYANAGI-HARADA DISEASE.
Park HS; Park HY; Lee CS; Lee SC; Lee JH
Retina; 2022 Dec; 42(12):2361-2367. PubMed ID: 36394890
[TBL] [Abstract][Full Text] [Related]
19. Early post-treatment choroidal thickness to alert sunset glow fundus in patients with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids.
Hirooka K; Saito W; Namba K; Mizuuchi K; Iwata D; Hashimoto Y; Ishida S
PLoS One; 2017; 12(2):e0172612. PubMed ID: 28241069
[TBL] [Abstract][Full Text] [Related]
20. Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up.
Herbort CP; Mantovani A; Bouchenaki N
Int Ophthalmol; 2007; 27(2-3):173-82. PubMed ID: 17457515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
